Heart failure (HF) is an enormous public health problem with over 500,000 cases annually, and African American individuals share a disproportionate amount of this burden including a higher prevalence and mortality when compared with white individuals. Beta adrenergic antagonists (beta-blockers, BB) are the foundation of modern HF care, but their effectiveness in African Americans is not clear. Pivotal clinical trials of BB in HF were woefully underpowered to assess African American patients, and many experts have suggested a differential BB benefit in African American patients when compared with white patients. This issue requires additional data and clarity because improved understanding and elimination of such disparities is a national research priority (Healthy People 2010). Multiple factors may contribute to a racial disparity in BB effect such as genetic factors, medication adherence, and comorbid illnesses. All of these factors must be characterized in detail in order to evaluate which factor(s) contribute to this. Existing pharmacogenetic studies have suggested that specific variants may explain racial differences in BB effectiveness, but these studies have not quantified drug exposure or adherence and have not included a sufficient number of African Americans. In order to answer these questions, we propose a racially diverse, prospective, pharmacogenomic registry of 1000 HF patients. Our center has important advantages to achieve this including the fact that roughly half of our HF patients are African American, and we have experience and infrastructure in quantifying adherence and drug exposure using pharmacy claims data. Using this cohort we will assess the influence of race and genetic factors on BB effectiveness, measured by clinical events (time to hospitalization or death) and health status. Ultimately these data will clarify the benefit of BB in African Americans, and contribute to improved targeting of BB therapy to those with highest likelihood of favorable response while avoiding those likely to respond unfavorably.

Public Health Relevance

Heart failure is an enormous public health problem and African American individuals share a disproportionate amount of this burden including a higher prevalence and mortality when compared with white individuals. Beta blockers are the foundation of modern heart failure care, but their effectiveness in African American individuals is not clear. This project seeks to clarify whether beta blockers are equally effective in African American patients when compared with white patients and identify the underlying factors that impact this difference, particularly genetic factors.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL103871-02
Application #
8287025
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Sopko, George
Project Start
2011-07-01
Project End
2016-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
2
Fiscal Year
2012
Total Cost
$672,286
Indirect Cost
$183,588
Name
Henry Ford Health System
Department
Type
DUNS #
073134603
City
Detroit
State
MI
Country
United States
Zip Code
48202
Amiri, Loabat; Cassidy-Bushrow, Andrea E; Dakki, Heather et al. (2014) Patient characteristics and participation in a genetic study: a type 2 diabetes cohort. J Investig Med 62:26-32
Lanfear, David E; Chow, Sheryl; Padhukasahasram, Badri et al. (2014) Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide. J Card Fail 20:662-8
Williams, L Keoki; Padhukasahasram, Badri; Ahmedani, Brian K et al. (2014) Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 99:3160-8
Hrobowski, Tara; Lanfear, David E (2013) Ventricular assist devices: is destination therapy a viable alternative in the non-transplant candidate? Curr Heart Fail Rep 10:101-7
Hayek, Sami; Canepa Escaro, Fabrizio; Sattar, Assad et al. (2013) Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol 111:532-9
Lanfear, David E; Sabbah, Hani N; Goldsmith, Steven R et al. (2013) Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail 6:47-52
Srivastava, Ajay V; Hrobowski, Tara; Krese, Lori et al. (2013) High rates of false-positive hepatitis C antibody tests can occur after left ventricular assist device implantation. ASAIO J 59:660-1
Lanfear, David E; Sunkara, Bipin; Li, Jia et al. (2013) Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway. J Cardiovasc Transl Res 6:826-33
El-Refai, Mostafa; Peterson, Edward L; Wells, Karen et al. (2013) Comparison of ?-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. J Card Fail 19:73-9
Lanfear, David E; Hrobowski, Tara N; Peterson, Edward L et al. (2012) Association of *-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail 5:202-8